Telaprevir Ups Response Rates Across IL28B Genotypes in Hepatitis C
Major Finding: Sustained virologic response rates in patients with the CT allele for IL28B were 71% with 12-week telaprevir plus pegylated interferon and ribavirin (PR), 57% with 8-week telaprevir plus PR, and 25% with PR alone, and in patients with the TT allele, rates were 73%, 59% and 23%, respectively.
Data Source: Unplanned post hoc genotype analysis of 454 patients in the phase III ADVANCE trial.
Disclosures: Dr. Jacobson disclosed numerous financial relationships with industry including grant support and other financial benefits from Tibotec and Vertex Pharmaceuticals, co-developers of telaprevir. Several co-authors also disclosed financial relationships including employment with Vertex.
FROM THE ANNUAL DIGESTIVE DISEASE WEEK
Further research, including studies on nonwhites, is needed to confirm these findings, Dr. Jacobson said.
Dr. Jacobson disclosed numerous financial relationships with industry including grant support and other financial benefits from Tibotec and Vertex Pharmaceuticals, which are developing telaprevir together. Several coauthors also disclosed financial relationships including employment with Vertex.
